Higher Expression of With Lower Expression may be Biomarkers for Risk Stratification of Patients With Cytogenetically Normal Acute Myeloid Leukemia.

Cytogenetics at diagnosis is the most important prognostic factor for adult acute myeloid leukemia (AML), but nearly 50% of AML patients who exhibit cytogenetically normal AML (CN-AML) do not undergo effective risk stratification. Therefore, the development of potential biomarkers to further define risk stratification for CN-AML patients is worth exploring. Transcriptome data from 163 cases in the GSE12417-GPL96 dataset and 104 CN-AML patient cases in the GSE71014-GPL10558 dataset were downloaded from the Gene Expression Omnibus database for overall survival (OS) analysis and validation. The combination of Wilms tumor 1 () and cluster of diffraction 58 () can predict the prognosis of CN-AML patients. High expression of and low expression of were associated with poor OS in CN-AML. Notably, when and were used to concurrently predict OS, CN-AML patients were divided into three groups: low risk, ; intermediate risk, or ; and high risk, 8. Compared with low-risk patients, intermediate- and high-risk patients had shorter survival time and worse OS. Furthermore, a nomogram model constructed with and may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rate of CN-AML patients. Both time-dependent receiver operating characteristics and calibration curves suggested that the nomogram model demonstrated good performance. Higher expression of with lower expression may be a potential biomarker for risk stratification of CN-AML patients. Moreover, a nomogram model constructed with and may personalize and reveal the 1-, 2-, 3-, 4-, and 5-year OS rates of CN-AML patients.